Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Correction: Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.

Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon MF, Judde JG, Cairo S, Goffin V.

Oncotarget. 2019 Jun 25;10(41):4249-4251. doi: 10.18632/oncotarget.27042. eCollection 2019 Jun 25.

2.

Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT.

Cancer Metastasis Rev. 2016 Dec;35(4):547-573. doi: 10.1007/s10555-016-9653-x. Review.

3.

Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents.

Gaston J, Cheradame L, Yvonnet V, Deas O, Poupon MF, Judde JG, Cairo S, Goffin V.

Oncotarget. 2016 Nov 22;7(47):77205-77224. doi: 10.18632/oncotarget.12858. Erratum in: Oncotarget. 2019 Jun 25;10(41):4249-4251.

4.

Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.

Legrier ME, Bièche I, Gaston J, Beurdeley A, Yvonnet V, Déas O, Thuleau A, Château-Joubert S, Servely JL, Vacher S, Lassalle M, Depil S, Tucker GC, Fontaine JJ, Poupon MF, Roman-Roman S, Judde JG, Decaudin D, Cairo S, Marangoni E.

Br J Cancer. 2016 Jan 19;114(2):177-87. doi: 10.1038/bjc.2015.398. Epub 2015 Dec 22.

5.

Patient-derived tumour xenografts as models for breast cancer drug development.

Marangoni E, Poupon MF.

Curr Opin Oncol. 2014 Nov;26(6):556-61. doi: 10.1097/CCO.0000000000000133. Review.

PMID:
25188472
6.

Ultrahigh dose-rate FLASH irradiation increases the differential response between normal and tumor tissue in mice.

Favaudon V, Caplier L, Monceau V, Pouzoulet F, Sayarath M, Fouillade C, Poupon MF, Brito I, Hupé P, Bourhis J, Hall J, Fontaine JJ, Vozenin MC.

Sci Transl Med. 2014 Jul 16;6(245):245ra93. doi: 10.1126/scitranslmed.3008973.

7.

Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model.

Barbosa-Desongles A, Hernández C, De Torres I, Munell F, Poupon MF, Simó R, Selva DM.

PLoS One. 2013 Sep 10;8(9):e74179. doi: 10.1371/journal.pone.0074179. eCollection 2013.

8.

Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.

Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E.

Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25.

9.

Risk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitors.

Guyader C, Céraline J, Gravier E, Morin A, Michel S, Erdmann E, de Pinieux G, Cabon F, Bergerat JP, Poupon MF, Oudard S.

PLoS One. 2012;7(8):e42252. doi: 10.1371/journal.pone.0042252. Epub 2012 Aug 6.

10.

[The metastatic process: history, models and recent advances].

Bidard FC, Poupon MF.

Med Sci (Paris). 2012 Jan;28(1):89-95. doi: 10.1051/medsci/2012281022. Epub 2012 Jan 27. Review. French.

11.

Molecular profiling of patient-derived breast cancer xenografts.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E.

Breast Cancer Res. 2012 Jan 16;14(1):R11.

12.

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.

Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16.

PMID:
22002565
13.

New criteria for analyzing the statistical relationships between biological parameters and therapeutic responses of xenografted tumor models.

Medioni J, Leuraud P, Delattre JY, Poupon MF, Golmard JL.

Contemp Clin Trials. 2012 Jan;33(1):178-83. doi: 10.1016/j.cct.2011.09.010. Epub 2011 Oct 1. Review.

PMID:
21986388
14.

In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma.

Aerts I, Leuraud P, Blais J, Pouliquen AL, Maillard P, Houdayer C, Couturier J, Sastre-Garau X, Grierson D, Doz F, Poupon MF.

Photodiagnosis Photodyn Ther. 2010 Dec;7(4):275-83. doi: 10.1016/j.pdpdt.2010.09.003. Epub 2010 Oct 16.

PMID:
21112551
15.

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.

de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E.

Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28.

16.

A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.

Dahmani A, de Plater L, Guyader C, Fontaine JJ, Berniard A, Assayag F, Beuzeboc P, Marangoni E, Némati F, Poupon MF, Pasik C, Oudard S, Decaudin D.

Anticancer Drugs. 2010 Nov;21(10):927-31. doi: 10.1097/CAD.0b013e32833db887.

PMID:
20827173
17.

ADP ribosylation factor like 2 (Arl2) regulates breast tumor aggressivity in immunodeficient mice.

Beghin A, Belin S, Hage-Sleiman R, Brunet Manquat S, Goddard S, Tabone E, Jordheim LP, Treilleux I, Poupon MF, Diaz JJ, Dumontet C.

PLoS One. 2009 Oct 15;4(10):e7478. doi: 10.1371/journal.pone.0007478. Erratum in: PLoS One. 2009;4(11):10.1371/annotation/b0d43779-c9aa-44fe-a46d-71d7d2bc4a6a. Hage Sleiman, Rouba [corrected to Hage-Sleiman, Rouba].

18.

Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.

Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D.

Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29.

PMID:
19823076
19.

Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts.

Némati F, Bras-Gonçalves R, Fontaine JJ, de Pinieux G, De Cremoux P, Chapelier A, Daniel C, Laurent-Puig P, Livartowski A, Judde JG, Bordier V, Poupon MF, Decaudin D.

Anticancer Drugs. 2009 Nov;20(10):932-40. doi: 10.1097/CAD.0b013e32833009cc.

PMID:
19741504
20.

Newly characterised ex vivo colospheres as a three-dimensional colon cancer cell model of tumour aggressiveness.

Weiswald LB, Richon S, Validire P, Briffod M, Lai-Kuen R, Cordelières FP, Bertrand F, Dargere D, Massonnet G, Marangoni E, Gayet B, Pocard M, Bieche I, Poupon MF, Bellet D, Dangles-Marie V.

Br J Cancer. 2009 Aug 4;101(3):473-82. doi: 10.1038/sj.bjc.6605173. Epub 2009 Jul 14.

21.

Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis.

Santamaria-Martínez A, Barquinero J, Barbosa-Desongles A, Hurtado A, Pinós T, Seoane J, Poupon MF, Morote J, Reventós J, Munell F.

Exp Cell Res. 2009 Oct 15;315(17):3004-13. doi: 10.1016/j.yexcr.2009.05.007. Epub 2009 May 15.

PMID:
19447103
22.

Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.

Guillamo JS, de Boüard S, Valable S, Marteau L, Leuraud P, Marie Y, Poupon MF, Parienti JJ, Raymond E, Peschanski M.

Clin Cancer Res. 2009 Jun 1;15(11):3697-704. doi: 10.1158/1078-0432.CCR-08-2042. Epub 2009 May 12.

23.

CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts.

Marangoni E, Lecomte N, Durand L, de Pinieux G, Decaudin D, Chomienne C, Smadja-Joffe F, Poupon MF.

Br J Cancer. 2009 Mar 24;100(6):918-22. doi: 10.1038/sj.bjc.6604953. Epub 2009 Feb 24.

24.

Hormone escape is associated with genomic instability in a human prostate cancer model.

Legrier ME, Guyader C, Céraline J, Dutrillaux B, Oudard S, Poupon MF, Auger N.

Int J Cancer. 2009 Mar 1;124(5):1103-11. doi: 10.1002/ijc.24073.

25.

p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.

Varna M, Lehmann-Che J, Turpin E, Marangoni E, El-Bouchtaoui M, Jeanne M, Grigoriu C, Ratajczak P, Leboeuf C, Plassa LF, Ferreira I, Poupon MF, Janin A, de Thé H, Bertheau P.

Int J Cancer. 2009 Feb 15;124(4):991-7. doi: 10.1002/ijc.24049.

26.

Time to metastatic relapse and breast cancer cells dissemination in bone marrow at metastatic relapse.

Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Rodrigues M, Diéras V, Mignot L, Sastre-Garau X, Poupon MF, Pierga JY.

Clin Exp Metastasis. 2008;25(8):871-5. doi: 10.1007/s10585-008-9203-1. Epub 2008 Nov 7.

PMID:
18989740
27.

Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B.

Lejmi E, Leconte L, Pédron-Mazoyer S, Ropert S, Raoul W, Lavalette S, Bouras I, Feron JG, Maitre-Boube M, Assayag F, Feumi C, Alemany M, Jie TX, Merkulova T, Poupon MF, Ruchoux MM, Tobelem G, Sennlaub F, Plouët J.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12491-6. doi: 10.1073/pnas.0804008105. Epub 2008 Aug 21.

28.

Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool.

Falguières T, Maak M, von Weyhern C, Sarr M, Sastre X, Poupon MF, Robine S, Johannes L, Janssen KP.

Mol Cancer Ther. 2008 Aug;7(8):2498-508. doi: 10.1158/1535-7163.MCT-08-0430. Epub 2008 Aug 7.

29.

[NM23 and metastasis suppressor genes: update].

Boissan M, Poupon MF, Lacombe ML.

Med Sci (Paris). 2007 Dec;23(12):1115-23. Review. French.

30.

A "class action" against the microenvironment: do cancer cells cooperate in metastasis?

Bidard FC, Pierga JY, Vincent-Salomon A, Poupon MF.

Cancer Metastasis Rev. 2008 Mar;27(1):5-10. Review.

31.

Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide.

Rezaï K, Lokiec F, Grandjean I, Weill S, de Cremoux P, Bordier V, Ekue R, Garcia M, Poupon MF, Decaudin D.

BMC Pharmacol. 2007 Oct 27;7:13.

32.

Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.

Némati F, Mathiot C, Grandjean I, Lantz O, Bordier V, Dewulf S, Ekue R, Di Santo JP, Poupon MF, Decaudin D.

Anticancer Drugs. 2007 Oct;18(9):1029-37.

PMID:
17704653
33.

A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF.

Clin Cancer Res. 2007 Jul 1;13(13):3989-98.

34.

Heterogeneous metastasis efficiency of isogenic orthotopic colon cancer xenografts reveals distinctive gene expression profiles.

Abal M, Fsihi H, Bras-Gonçalves R, Doll A, Boyé K, Janssen KP, Alameda F, Reventós J, Louvard D, Magdelenat H, Poupon MF, Robine S.

Tumour Biol. 2007;28(3):139-50. Epub 2007 May 18.

PMID:
17519533
35.
36.

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels.

Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH, Poupon MF, Azzarello A, Pinedo HM, Peters GJ.

Br J Cancer. 2007 Mar 12;96(5):769-75.

37.

Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.

Legrier ME, Oudard S, Judde JG, Guyader C, de Pinieux G, Boyé K, de Cremoux P, Dutrillaux B, Poupon MF.

Br J Cancer. 2007 Jan 29;96(2):269-76. Epub 2007 Jan 9.

38.

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features.

Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, Poupon MF.

Cancer Res. 2007 Jan 1;67(1):398-407.

39.

Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.

Judde JG, Rebucci M, Vogt N, de Cremoux P, Livartowski A, Chapelier A, Tran-Perennou C, Boye K, Defrance R, Poupon MF, Bras-Gonçalves RA.

Int J Cancer. 2007 Apr 1;120(7):1579-90.

40.

[Cancer xenografts in humans: opportunity for modeling cancer disease in humans and it's treatment].

Poupon MF.

Ann Pathol. 2006 Nov;26 Spec No 1:1S51-3. French. No abstract available.

PMID:
17149178
41.

Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line.

Auger N, Thillet J, Wanherdrick K, Idbaih A, Legrier ME, Dutrillaux B, Sanson M, Poupon MF.

Mol Cancer Ther. 2006 Sep;5(9):2182-92.

42.

High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.

Decaudin D, Marszak FB, Couturier J, Mathiot C, Martin A, Némati F, Lantz O, Santo Jd, Arnaud P, Bordier V, Vincent-Salomon A, Poupon MF.

Anticancer Drugs. 2006 Jul;17(6):685-95.

PMID:
16917214
43.

Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.

Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.

J Clin Oncol. 2005 May 20;23(15):3343-51. Epub 2005 Feb 28.

PMID:
15738542
44.

Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis.

Bavoux C, Leopoldino AM, Bergoglio V, O-Wang J, Ogi T, Bieth A, Judde JG, Pena SD, Poupon MF, Helleday T, Tagawa M, Machado C, Hoffmann JS, Cazaux C.

Cancer Res. 2005 Jan 1;65(1):325-30.

45.

[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].

de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY.

Bull Cancer. 2004 Dec;91(12):917-27. Review. French.

46.

Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells.

Soulié P, Carrozzino F, Pepper MS, Strongin AY, Poupon MF, Montesano R.

Oncogene. 2005 Mar 3;24(10):1689-97.

PMID:
15608664
47.

Homophilic anchorage of brain-hexokinase to mitochondria-porins revealed by specific-peptide antibody cross recognition.

Oudard S, Miccoli L, Beurdeley-Thomas A, Dutrillaux B, Poupon MF.

Bull Cancer. 2004 Jun;91(6):E184-200.

48.

In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy.

Decaudin D, de Cremoux P, Sastre X, Judde JG, Nemati F, Tran-Perennou C, Fréneaux P, Livartowski A, Pouillart P, Poupon MF.

Int J Cancer. 2005 Feb 20;113(5):849-56. Review.

49.

Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts.

Carnesecchi S, Bras-Gonçalves R, Bradaia A, Zeisel M, Gossé F, Poupon MF, Raul F.

Cancer Lett. 2004 Nov 8;215(1):53-9.

PMID:
15374632
50.

Supplemental Content

Loading ...
Support Center